secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0000950170-22-020881
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics enters exclusive CDMO partnership with Emergent BioSolutions for polyclonal antibodies
--------------------------------------------------------------------------------

- Emergent to provide end-to-end cGMP manufacturing services for SAB's fully-human polyclonal antibody products.
- Emergent gets exclusive option to commercial manufacture SAB's products and right of first refusal on three therapeutic areas: botulism, pandemic influenza, anti-fungal.
- SAB's DiversitAb platform uses transchromosomic cows to produce fully-human polyclonal antibodies without human donors.
- Financial terms not disclosed; partnership covers both clinical and potential commercial manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017022020881/0000950170-22-020881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017022020881/sabs-20221026.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-020881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer